BI 754091

Drug Profile

BI 754091

Alternative Names: BI754091

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 16 Mar 2018 Boehringer Ingelheim plans a phase I trial of BI 754091 in combination with BI 836880 for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease), in April 2018 (NCT03468426)
  • 15 Feb 2018 Boehringer Ingelheim plans a phase I trial in Solid tumours (Monotherapy, Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater)(NCT03433898)
  • 18 Sep 2017 Boehringer Ingelheim initiates enrolment in a phase I trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/ Unresectable, Second-line therapy or greater) in USA (NCT03166631)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top